Promatix Biosciences Ltd was launched by ALSA Ventures in February 2020. Incubated within ALSA’s investment team, and run from its London office, the founding management team has a successful track record of drug development from inception to regulatory approval.
Our proteomic database, TxPro, is one of the largest known database of its type, with thousands of primary tissue samples sourced and analysed in both healthy and diseased states.
TxPro is used to discover and validate novel drug targets through differential protein expression and presentation analysis in diseased and normal tissue.
The Promatix team carefully selects the most promising drug targets in silico to develop treatments for cancer.
